article · Pharmacopsychiatry
Melperone is a neuroleptic medication commonly prescribed for its sleep-inducing effects. An open pilot study assessed how melperone alters blood concentrations of venlafaxine, an antidepressant metabolised by the cytochrome P450 enzyme CYP2D6. Analysis of therapeutic drug-monitoring records from ninety-four patients revealed that individuals taking both drugs had significantly higher venlafaxine and lower O-desmethylvenlafaxine concentrations than those not taking melperone. In a subset of three monitored patients, venlafaxine blood levels rose by an average of 52 percent during melperone co-administration, while O-desmethylvenlafaxine dropped by 29 percent. Furthermore, tests in seven patients using dextromethorphan as a metabolic probe showed that three days of melperone treatment significantly elevated the dextromethorphan to dextrorphan ratio. These results demonstrate that melperone inhibits CYP2D6-mediated drug metabolism.
Understanding how psychiatric medications interact is vital for patient safety and effective dosing. Because melperone is frequently prescribed to aid sleep, its ability to inhibit the CYP2D6 enzyme means it can substantially raise blood levels of other drugs, such as venlafaxine. This insight allows healthcare practitioners to anticipate drug interactions, prevent unintended adverse effects, and adjust doses appropriately when these medications are co-prescribed.
This clinical evidence informs drug-safety databases, clinical decision support software, and therapeutic drug-monitoring protocols used by hospitals and pharmacies. The work represents applied clinical research based on patient data, making it directly relevant to healthcare providers managing psychiatric co-medications. While it does not introduce a novel product, it provides actionable interaction data that can be incorporated into existing clinical prescribing systems to guide safe co-administration.
AI-generated from the published abstract. Always read the original work before citing.
INTRODUCTION: Melperone, a butyrophenone neuroleptic, is frequently used for its sleep-inducing properties. Despite its common use for more than 30 years, it is not yet characterized regarding its effects on cytochrome P450 s (CYPs). In an open pilot study, effects of melperone on the steady-state blood levels of venlafaxine, a recently introduced serotonin- and noradrenaline reuptake inhibiting antidepressant, were assessed. METHODS: The dose-corrected serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed retrospectively in a therapeutic drug-monitoring (TDM) database comprising 94 patients. In addition, three patients received venlafaxine and melperone concomitantly and the serum concentrations of venlafaxine and O-desmethylvenlafaxine were analyzed before, during, and after melperone co-medication. The effect of melperone on CYP2D6 was further assessed in seven patients by means of the dextromethorphan O-demethylation, which serves as a CYP2D6 probe reaction. RESULTS: Patients treated concomitantly with venlafaxine and melperone had significantly higher (mean +/- SD) venlafaxine (3.27 +/- 2.9 vs. 0.97 +/- 0.99 ng/ml per mg/d; p < 0.05) and lower O-desmethylvenlafaxine serum concentrations (0.69 +/- 0.35 vs. 1.51 +/- 0.9 ng/ml per mg/d; p < 0.01) compared to patients without melperone comedication. In the three patients, venlafaxine serum concentrations increased, on average by 52 % during melperone co-medication, whereas O-desmethylvenlafaxine was decreased, on average by 29 %. Administration of melperone over three days elevated the ratio of dextromethorphan to dextrorphan from 0.044 +/- 0.04 to 0.09 +/- 0.083 (p < 0.05). DISCUSSION: This study pointed to an inhibitory effect of melperone on the O-demethylation of venlafaxine. Because the O-demethylation of venlafaxine is almost exclusively catalyzed by CYP2D6 it is concluded that melperone is an inhibitor of CYP2D6. The hypothesis was further corroborated by the inhibitory effect of melperone on the dextromethorphan O-demethylation.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1055/s-2003-38084
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
